Skip to main content

Table 3 Clinical trials evaluating biomarkers of response in HCC patients treated by immunotherapy

From: Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma

Identifier No. Biomarker type Treatment Patients
NCT05044676 Circulating Immune Cells Atezolizumab/Bevacizumab Advanced HCC
NCT04965454 (ExTRACT-HCC) Genomic liquid biopsy based biomarkers ICIs Inoperable HCC
NCT03895970 Not specified Lenvatinib plus Pembrolizumab Advanced hepatobiliary tumors
NCT04642664 (ACABC) Not specified Apatinib plus Camrelizumab Hepatobiliary Neoplasm
NCT03595813 (IMMUNO-SUP) Plasma immunosuppressive actors ICIs Locally advanced or metastatic solid tumor
NCT03514368 (MINER) Immunological biomarkers from blood samples ICIs, alone or in combination Any advanced solid tumor